How to Prescribe Peptides
A practical workflow for clinicians who want to evaluate peptide therapy without improvising the indication review, consent packet, compounded/off-label disclosures, and chart documentation.
Core idea
The safest peptide workflow is operationally boring.
Strong peptide prescribing workflows are not built on one perfect monograph or one clever script. They are built on repeatable steps: define the indication, clarify product status, explain risks and alternatives, document patient understanding, and keep the chart note aligned with the packet.
This page is intentionally about workflow, not dosing advice for any one peptide. Use it to tighten your process before you spend more time on sourcing or protocol details.
Best fit for this page
- Clinicians evaluating whether peptide therapy belongs in the practice at all
- Practices that need a cleaner approved-versus-compounded decision workflow
- Teams trying to standardize consent and charting before scaling patient volume
A practical prescribing workflow
1. Start with the indication, not the peptide
Define the patient problem, prior therapies, treatment goal, and why a peptide is being considered now. Do this before discussing sourcing, brand names, or social-media narratives.
2. Decide whether you are discussing an approved drug, compounded product, or both
The product-status question changes the whole workflow. Your evidence discussion, consent packet, and sourcing diligence should match the actual route you are considering.
3. Build the consent packet before you build the script
Use a base peptide consent, then layer in GLP-1, off-label, or compounded-medication disclosures when applicable. A consistent packet keeps staff, charting, and patient expectations aligned.
4. Document like the conversation could be audited later
Your note should describe the rationale, alternatives discussed, patient questions, material risks, product-status explanation, and follow-up plan in the same language your packet uses.
Common mistakes to avoid
- Starting with protocol shortcuts before the indication and evidence discussion are clear.
- Treating compounded and approved products as interchangeable in patient-facing language.
- Using one generic waiver instead of a packet that reflects off-label or compounded status.
- Letting the peptide-source conversation outrun the documentation and patient-understanding process.
Product-status discipline
Do not let "peptides" flatten important regulatory differences.
The word "peptide" hides important differences between approved products, compounded products, off-label use, and higher-scrutiny substances. Your workflow should force clarity on that point early because the rest of the patient conversation depends on it.
If the product is compounded, your sourcing diligence, consent language, and charting should all reflect that. If the use is off-label, document that explicitly. If the regulatory posture is uncertain or contentious, tighten the explanation rather than softening it.
What to open next
The fastest way to operationalize this workflow is to open the right surfaces in order.
Start with documentation and product-status context. Move into protocols only after the patient conversation, consent packet, and chart note structure are settled.
Open the public template library and see the individual forms.
Review 503A, 503B, shortages, and broader compounding context.
Use protocols after the documentation and product-status workflow is clear.
Get the complete packet, editable files, and implementation checklist.